Skip to main content
OpenTrials

Clinical trial condition

Lymphoma

Explore clinical trials studying Lymphoma. Study availability and eligibility vary by location and protocol.

3,646 public trials 848 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma trial results

Active, Not Recruiting

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

NCT03474744

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Med. Uni Wien AKH, Klinische Abteilung für Onkologie, Innere Medizin I Vienna, Austria
  • St. Josef-Hospital, Medizinische Klinik I Bochum, Germany
  • Johanniter GmbH, Johanniter-Krankenhaus Bonn, Germany
  • ÜBAG MVZ Dr. Vehling-Kaiser GmbH Dingolfing Dingolfing, Germany
View all 18 locations
View Trial Details
Active, Not Recruiting

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

NCT01920932

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +9 more
Locations
  • Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States
  • St. Jude Midwest Affiliate Peoria, Illinois, United States
  • Maine Children's Cancer Program (MCCP) Scarborough, Maine, United States
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
View Trial Details
Active, Not Recruiting

Obinutuzumab in Marginal Zone Lymphoma

NCT03322865

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Augusta-Kranken-Anstalt gGmbH Bochum, Germany
  • University Hospital Essen Essen, Germany
  • Universitätsklinikum Freiburg Freiburg im Breisgau, Germany
  • Universitätsmedizin Georg-August-University Göttingen, Germany
View Trial Details
Active, Not Recruiting

A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China

NCT07226752

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Affiliated Hospital of Hebei University Baoding, China
  • Beijing Cancer Hospital Beijing, China
  • Beijing Tongren Hospital, Capital Medical University Beijing, China
  • Peking University Third Hospital Beijing, China
View all 23 locations
View Trial Details
Active, Not Recruiting

Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas

NCT05400109

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
  • University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States
View Trial Details
Active, Not Recruiting

Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)

NCT05429268

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Medical University Plovdiv Plovdiv, Bulgaria
  • Acibadem Cityclinica Mhat Tokuda Sofia, Bulgaria
  • Umhat Alexandrovska Sofia Sofia, Bulgaria
  • Umhat Sv. Ivan Rilski Ead Sofia, Bulgaria
View all 61 locations
View Trial Details

Related conditions